Research and Markets: European Markets for Computer-Aided Detection: focusing on the breast, chest, colon, prostate, liver and bone

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/f7ab73/european_markets_f) has announced the addition of Frost & Sullivan's new report "European Markets for Computer-Aided Detection" to their offering.

This research service provides a comprehensive analysis of the European Computer aided detection market. It includes an analysis of the challenges affecting the industry, factors driving and restraining the growth of the market and opportunities that participants can look forward to during the forecast period of 2010 to 2017. The report focuses on the European Breast, Chest, Colon, Prostate, Liver and Bone CAD markets. The study also analyzes the supply chain management of the CAD market. A detailed competitive analysis of market participants in the form of a SWOT analysis along with their product portfolio is also given.

This Frost & Sullivan research service titled European Markets for Computer Aided Detection provides a comprehensive analysis of the challenges affecting the industry, factors driving and restraining the growth of the market and opportunities that participants can look forward to during the forecast period, which extends from 2010 to 2017. The research focuses on the European breast, lung and colon computer-aided design (CAD) markets, while discussing newer areas like osteo (bone) CAD and trends in other CAD applications such as prostate and liver CAD.

Report Highlights:

• The European computer-aided detection (CAD) market is poised for growth, due to the need for digitisation and highly automated integrated workflow.
• Hospitals today are transitioning to digitisation. High patient mobility requires easy portability of patient records. Multi-modal imaging solutions like PET/CT, PET/MRI and hybrid modal solutions like SPECT/CCTA have hit the market.
• The greatest market challenge is the need for evidentiary support, from large-scale clinical trials, proving the accuracy of CAD solutions. Establishing that CAD solutions reduce the number of false positives in detection of cancerous growth will be critical to continued market expansion.
• Governmental regulations and ambiguous reimbursement procedures are as potential obstacles to market growth. They are likely to hamper the adoption of newer applications such as lung and colon CAD. Companies need to invest a great deal of time and money in staying up-to-date with technological improvements, new products, innovative techniques as well as market opportunities and regulatory changes, concludes the analyst.

For more information visit http://www.researchandmarkets.com/research/f7ab73/european_markets_f